Risk factors for hepatic encephalopathy after emergency transjugular intrahepatic portosystemic shunt for patients with acute esophagogastric variceal bleeding

Yao YunHai; Luo Yan; Zhu JingLe; Gan JianHe; Zhao WeiFeng

doi:10.3969/j.issn.1001-5256.2020.02.022

Volume 36 Issue 2

Feb. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(2): 343-347

PDF( 1966 KB)

Risk factors for hepatic encephalopathy after emergency transjugular intrahepatic portosystemic shunt for patients with acute esophagogastric variceal bleeding

DOI: 10.3969/j.issn.1001-5256.2020.02.022

Department of Infectious Diseases/Intensive Care Unit of Hepatology,The First Hospital Affiliated of Soochow University

Research funding:

Received Date: 2019-09-18
Published Date: 2020-02-20

Abstract

Abstract

Objective To investigate the risk factors for hepatic encephalopathy( HE) after emergency transjugular intrahepatic portosystemic shunt( TIPS) for patients with acute esophagogastric variceal bleeding( EVB) based on an analysis of clinical outcomes. Methods A retrospective analysis was performed for the clinical data of 93 patients with decompensated liver cirrhosis and acute EVB who failed endoscopy or medication and then underwent TIPS with a covered stent within 72 hours in The First Affiliated Hospital of Soochow University from January 2013 to December 2018. According to the presence or absence of HE after surgery,they were divided into HE group with 36 patients and non-HE group with 57 patients. Preoperative clinical data were collected,including sex,age,etiology,comorbidities,and blood biochemical parameters [white blood cell count( WBC),platelet count( PLT),hematocrit( Hct),total bilirubin( TBil),aspartate aminotransferase( AST),albumin( Alb),serum creatinine( SCr),and prothrombin time( PT) ],and the measured values were used to calculate Model for End-Stage Liver Disease( MELD) score. Wedged hepatic venous pressure( WHVP) and free hepatic venous pressure( FHVP) were measured and recorded before TIPS stent implantation,and hepatic venous pressure gradient( HVPG) was the difference between WHVP and FHVP. The t-test or the Mann-Whitney U test was used for comparison between two groups,and the chi-square test was used for comparison of categorical data between two groups. A binary logistic regression analysis was used to identify the risk factors for the prognosis of patients after TIPS. Results The incidence rate of postoperative HE was 38. 710%. There were significant differences between the two groups in preoperative MELD score( 13. 000 ± 3. 189 vs 11. 684 ± 2. 068,t = 2. 068,P = 0. 043) and HVPG( 24. 908 ±5. 317 mm Hg vs 22. 597 ± 4. 928 mm Hg,t = 2. 100,P = 0. 039). Based on the results of HE grading,17 patients( 47. 222%) had grade0-1 HE,9( 25. 000%) had grade 2 HE,6( 16. 667%) had grade 3 HE,and 4( 11. 111%) had grade 4 HE. The stepwise logistic regression analysis showed that MELD score( odds ratio [OR]= 0. 803,95% confidence interval [CI]: 0. 679-0. 948,P = 0. 010) and HVPG( OR = 0. 896,95% CI: 0. 816-0. 984,P = 0. 022) were independent risk factors for HE after TIPS. Conclusion There is a high incidence rate of HE after emergency TIPS for acute EVB,and preoperative MELD score and HVPG can predict the risk of HE after TIPS.
- esophageal and gastric varices,
- hepatic encephalopathy,
- risk factors

FullText(HTML)

References(25)

References

[1] HE FL,WANG L,YUE ZD,et al. Parallel transjugular intrahepatic portosystemic shunt for controlling portal hypertension complications in cirrhotic patients[J]. World J Gastroenterol,2014,20(33):11835-11839.

[2] YU ZG,LIN YH,HUANG WF,et al. Clinical efficacy and safety of different endoscopy methods in patients with liver cirrhosis complicated with esophagogastric varicosity bleeding[J]. J Clin Exp Med,2018,17(8):813-816.(in Chinese)余中贵，林燕华，黄文峰，等．不同内镜方案对肝硬化合并食管胃底静脉曲张破裂出血患者临床疗效及安全性分析[J]．临床和实验医学杂志，2018,17(8):813-816.

[3] GARCIA-TG,ABRALDES JG,BERZIGOTTI A,et al. Portal hypertensive bleeding in cirrhosis:Risk stratification,diagnosis,and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology,2017,65(1):310-335.

[4] PAPATHEODORIDIS GV,GOULIS J,LEANDRO G,et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding:A metaanalysis[J]. Hepatology,1999,30(3):612-622.

[5] Portal hypertension group of Chinese Surgery Branch. Consensus diagnosis and treatment of cirrhotic portal hypertension with esophageal and gastric varices bleeding(2015 edition)[J]. Chin J Gen Surg,2016,31(2):167-170.(in Chinese)中华外科学分会门静脉高压症学组．肝硬化门静脉高压症食管胃底静脉曲张破裂出血的诊治共识(2015版)[J]．中华普通外科杂志，2016,31(2):167-170.

[6] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol,2018,34(10):2076-2089.(in Chinese)中华医学会肝病学分会．肝硬化肝性脑病诊疗指南[J]．临床肝胆病杂志，2018,34(10):2076-2089.

[7] MASSON S,MARDINI HA,ROSE JD,et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion:A decade of experience[J]. QJM,2008,101(6):493-501.

[8] Chinese Portal Hypertension Diagnosis and Monitoring Study Group(CHESS); Minimally Invasive Intervention Collaborative Group,Chinese Society of Gastroenterology; Emergency Intervention Committee,Chinese College of Interventionalists,et al. Consensus on clinical application of hepatic venous pressure gradient in China(2018)[J]. J Clin Hepatol,2018,34(12):2526-2536.(in Chinese)中国门静脉高压诊断与监测研究组(CHESS)，中华医学会消化病学分会微创介入协作组，中国医师协会介入医师分会急诊介入专业委员会，等．中国肝静脉压力梯度临床应用专家共识(2018版)[J]．临床肝胆病杂志，2018,34(12):2526-2536.

[9] LU W,YANG C,ZHANG JC,et al. The effect of wedged hepatic venography with CO2during TIPS in the treatment of acute upper gastro-intestinal bleeding in liver cirrhosis[J].China Med Herald,2019,16(10):84-87.(in Chinese)卢伟，杨超，张嘉诚，等．CO2楔入肝静脉造影在肝硬化急性上消化道出血的TIPS术中的作用[J]．中国医药导报，2019,16(10):84-87.

[10] LYU Y,ZUO L,ZHU X,et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding:A multicentre observational study[J]. Gut,2019,68(7):1297-1310.

[11] SIRAMOLPIWAT S. Transjugular intrahepatic portosystemic shunts and portal hypertension related complications[J]. World J Gastroenterol,2014,20(45):16996-17010.

[12] FERENCI P,LOCKWOOD A,MULLEN K,et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification:Final report of the working party at the 11th World Congresses of Gastroenterology[J]. Hepatology,2002,35(3):716-721.

[13] ABRALDES JG,TANDON P. Therapies:Drugs,scopes and transjugular intrahepatic portosystemic shunt--when and how?[J]. Dig Dis,2015,33(4):524-533.

[14] MENDEZ M,MENDEZ-LOPEZ M,LOPEZ L,et al. Portosystemic hepatic encephalopathy model shows reversal learning impairment and dysfunction of neural activity in the prefrontal cortex and regions involved in motivated behavior[J]. J Clin Neurosci,2011,18(5):690-694.

[15] LUO X,ZHAO M,WANG X,et al. Long-term patency and clinical outcome of the transjugular intrahepatic portosystemic shunt using the expanded polytetrafluoroethylene stent-graft[J]. PLo S One,2019,14(2):e0212658.

[16] RIGGIO O,NARDELLI S,MOSCUCCI F,et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Clin Liver Dis,2012,16(1):133-146.

[17] PEREIRA K,CARRION AF,MARTIN P,et al. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy[J]. Liver Int,2015,35(12):2487-2494.

[18] AHMED R,SANTHANAM P,RAYYAN Y. MELD-Na as a prognostic indicator of 30-and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt[J]. Eur J Gastroenterol Hepatol,2015,27(10):1226-1227.

[19] LUCIDI C,LATTANZI B,RIGGIO O,et al. May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?[J]. J Hepatol,2018,68(6):1324-1325.

[20] MALINCHOC M,KAMATH PS,GORDON FD,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology,2000,31(4):864-871.

[21] NARDELLI S,GIOIA S,PASQUALE C,et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Am J Gastroenterol,2016,111(4):523-528.

[22] KIM TY,LEE JG,SOHN JH,et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis[J]. Yonsei Med J,2016,57(1):138-145.

[23] AMESUR NB,NOVELLI P. Transjugular intrahepatic portosystemic shunt[M]. Stat Pearls. Treasure Island(FL):Stat Pearls Publishing,2019.

[24] ZIVON AS,CHEN L,KAUFMAN J,et al. The degree in reduction of portal-systemic gradient during tips and not final post-tips portal pressure gradient is predictive of the development of hepatic encephalopathy[J]. Gastroenterology,2014,1461(5):s932.

[25] CHUNG HH,RAZAVI MK,SZE DY,et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft:What is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?[J]. J Gastroenterol Hepatol,2008,23(1):95-101.

Relative Articles

[1]	Guodong SHI, Zipeng LU, Kuirong JIANG. Diagnosis and treatment of dyspepsia associated with pancreatic tumors[J]. Journal of Clinical Hepatology, 2023, 39(12): 2770-2774. doi: 10.3969/j.issn.1001-5256.2023.12.004
[2]	Yi YAN, Junmei JIA, Yarong GUO. Role of cancer-associated fibroblasts in drug resistance of pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(5): 1203-1208. doi: 10.3969/j.issn.1001-5256.2022.05.048
[3]	Yiyi ZHANG, Min XU. Research advances in the mechanism of tumor microenvironment in pancreatic cancer and related targeted therapy[J]. Journal of Clinical Hepatology, 2022, 38(4): 965-968. doi: 10.3969/j.issn.1001-5256.2022.04.046
[4]	Lina BAI, Ying LIU, Chunxiao TANG, Hongxin PIAO, Zhenhua LIN, Wanshan YANG, Aihua JIN. Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells[J]. Journal of Clinical Hepatology, 2022, 38(12): 2793-2801. doi: 10.3969/j.issn.1001-5256.2022.12.020
[5]	Jing WANG, Bin TAN, Zhijie ZHAO, Haochen ZHONG, Linlin QU. Genomic profile of pancreatic tumor in the coastal regions of Eastern China: A multicenter analysis of 40 cases[J]. Journal of Clinical Hepatology, 2022, 38(2): 409-414. doi: 10.3969/j.issn.1001-5256.2022.02.028
[6]	Feiyu ZHANG, Yakepu ADILA, Jinming ZHAO, Yanhang GAO. New advances in the treatment of pancreatic cancer by targeting tumor microenvironment[J]. Journal of Clinical Hepatology, 2021, 37(9): 2246-2248. doi: 10.3969/j.issn.1001-5256.2021.09.049
[7]	Zhang Yu, Jiang JianXin. Biological role of hypoxic microenvironment in pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(3): 708-712. doi: 10.3969/j.issn.1001-5256.2020.03.054
[8]	Wang Kun, ABUDUREYIMU·Tuerhong, Yang Fan, Liu YaHui, Fu Yu, Zhang Wei. Endoscopic pancreatic stent placement combined with tumor enucleation for benign pancreatic neck tumor: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 185-186. doi: 10.3969/j.issn.1001-5256.2019.01.040
[9]	Yang GuiMin, Zhao YunSheng, Wang ChunHua, Jin Liang. Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 199-203. doi: 10.3969/j.issn.1001-5256.2018.01.044
[10]	Zheng SuLi, Zhang TaiPing. An excerpt of laparoscopic surgery for pancreatic neoplasms: the European Association for Endoscopic Surgery clinical consensus conference（2017）[J]. Journal of Clinical Hepatology, 2017, 33(5): 816-819. doi: 10.3969/j.issn.1001-5256.2017.05.004
[11]	Lu: Yan, Zhang XiaoWen. Classification and diagnosis of pancreatic cystic neoplasm[J]. Journal of Clinical Hepatology, 2016, 32(5): 968-971. doi: 10.3969/j.issn.1001-5256.2016.05.039
[12]	Liu Xu, Guo XiaoZhong. Early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2016, 32(5): 864-866. doi: 10.3969/j.issn.1001-5256.2016.05.008
[13]	Yang XiaoXiao, Ma Hong. Research advances in tumor markers of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 811-815. doi: 10.3969/j.issn.1001-5256.2016.04.047
[14]	Li Zhao, Zhu JiYe. Treatment of pancreatic neuroendocrine tumor with liver metastases[J]. Journal of Clinical Hepatology, 2015, 31(5): 668-670. doi: 10.3969/j.issn.1001-5256.2015.05.007
[15]	Hou XiaoJia, Jin ZhenDong. Progress in additional new techniques of endoscopic ultrasound in treatment of pancreatic tumors[J]. Journal of Clinical Hepatology, 2015, 31(5): 671-673. doi: 10.3969/j.issn.1001-5256.2015.05.008
[16]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of pancreatic neuroendocrine neoplasms (2014)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1246-1248. doi: 10.3969/j.issn.1001-5256.2014.12.004
[17]	Li XiaoQing, Qian JiaMing. Differentiation between gastrointestinal neuroendocrine tumors and pancreatic neuroendocrine tumors[J]. Journal of Clinical Hepatology, 2013, 29(7): 492-495. doi: 1001-5256 (2013) 07-0492-04
[18]	Chen Jie. Pathological and differential diagnoses of exocrine pancreatic tumors[J]. Journal of Clinical Hepatology, 2013, 29(1): 45-49.
[19]	Zhang WenYing, Jin ZhenDong. Endoscopic ultrasound -guided treatment for pancreatic tumor[J]. Journal of Clinical Hepatology, 2012, 28(8): 573-575+578.
[20]	Wang YaJun, Sun JiaBang. Experience in diagnosis and treatment of pancreatic cystic tumors[J]. Journal of Clinical Hepatology, 2010, 26(5): 472-475+489.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	陶丽莹，王宏光，郭庆梅，朴连玉，郭享，阮丽斌，刘时助，孙震. 内镜逆行胰胆管造影联合eyeMax胆胰成像系统直视下液电碎石治疗困难胆管结石效果观察. 临床肝胆病杂志. 2024(02): 351-355 . 本站查看
2.	刘姣，朱巧，范建梅. 内镜逆行胰胆管造影术中使用胰胆直视成像系统联合激光碎石治疗胆总管复杂结石的分析. 医学研究与战创伤救治. 2024(02): 177-180 .
3.	刘晓艳，杨亚苹，韩文雄. 多层螺旋计算机断层扫描技术与磁共振胰胆管造影技术诊断胆总管结石的临床价值. 包头医学. 2024(02): 10-12 .
4.	马丽娜·阿新拜，张立平，王林恒，王允亮，陈润花，孟捷，胡立明，姚玉璞. 经ERCP联合SpyGlass DS治疗的74例不明原因胆管狭窄患者的临床特征分析. 胃肠病学和肝病学杂志. 2024(08): 1037-1044 .
5.	艾合买江·库尔班江，布娅·米然别克，王秋玲，李得阳，高峰. SpyGlass DS系统联合激光碎石法与常规分次治疗胆总管大结石的效果和安全性的对比分析. 中国内镜杂志. 2024(08): 12-17 .
6.	郭志新，王俊，余晓，关天佑，于芳芳. NTrap网篮联合输尿管软镜钬激光术治疗上段输尿管结石的效果及预后观察. 医药论坛杂志. 2024(16): 1703-1707 .
7.	叶国华，姜继豪，王小方. 腹腔镜下联合胆道镜、术中超声及液电碎石仪治疗复杂肝内胆管结石的效果. 中国当代医药. 2024(31): 20-23 .
8.	刘杨军，李纪男. ERCP治疗高龄胆总管结石的效果. 中国老年学杂志. 2024(24): 5935-5937 .
9.	王毅兰，李喆楠，王军民. SpyGlass在胆胰疾病诊治中的研究进展. 河北医科大学学报. 2023(02): 241-245 .
10.	刘炯，汪向飞，江斌. SpyGlass系统在困难胆囊腹腔镜胆囊切除术中的应用价值. 临床外科杂志. 2023(10): 925-927 .
11.	濮天，陈江明，郭旗，蒋东，李子寒，刘付宝，耿小平. 精准肝切除术治疗复发性单侧肝内胆管结石的临床疗效及预后影响因素分析. 中华消化外科杂志. 2022(02): 273-280 .
12.	陈安，柏强善，谭凯. 对胆囊结石合并胆总管结石的老年患者实施腹腔镜胆囊切除术联合内镜逆行胰胆管造影术的临床疗效. 中国内镜杂志. 2022(11): 57-64 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1202) PDF downloads(211)

Risk factors for hepatic encephalopathy after emergency transjugular intrahepatic portosystemic shunt for patients with acute esophagogastric variceal bleeding

DOI: 10.3969/j.issn.1001-5256.2020.02.022